Medicinal chemistry is continually developing and testing new drugs and drug candidates to satisfactorily
address the needs of patients suffering from schizophrenia. In the last few years, some significant additions
have been made to the list of widely available atypical antipsychotics. In particular, iloperidone, asenapine and lurasidone
have been approved by the USA's Food and Drug Administration in 2009-10.
In this paper, the most notable metabolic characteristics of these new drugs are addressed, with particular attention to their potential for
pharmacokinetic interactions, and to the respective advantages and disadvantages in this regard.
Moreover, current perspectives on the therapeutic drug monitoring (TDM) of the considered drugs are discussed. Since TDM is most
valuable when it allows the personalisation and optimisation of therapeutic practices, it is even more interesting in the case of novel
drugs, such as those discussed here, whose real impact in terms of side and toxic effects on very large populations is still unknown. Some
analytical notes, related to TDM application, are included for each drug.